Read more about the article Perspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy
Perspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy

Perspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy

Perspective Therapeutics advances [212Pb]VMT-α-NET trial into Cohort 3, assessing higher doses for treating neuroendocrine tumors.Quiver AI SummaryPerspective Therapeutics, Inc. announced that its Phase 1/2a clinical trial for [212Pb]VMT-α-NET is moving…

Continue ReadingPerspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy

End of content

No more pages to load

Newer Posts
Older Posts